BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 21696628)

  • 1. Physiologic and molecular consequences of endothelial Bmpr2 mutation.
    Majka S; Hagen M; Blackwell T; Harral J; Johnson JA; Gendron R; Paradis H; Crona D; Loyd JE; Nozik-Grayck E; Stenmark KR; West J
    Respir Res; 2011 Jun; 12(1):84. PubMed ID: 21696628
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic ablation of the BMPR2 gene in pulmonary endothelium is sufficient to predispose to pulmonary arterial hypertension.
    Hong KH; Lee YJ; Lee E; Park SO; Han C; Beppu H; Li E; Raizada MK; Bloch KD; Oh SP
    Circulation; 2008 Aug; 118(7):722-30. PubMed ID: 18663089
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytoskeletal defects in Bmpr2-associated pulmonary arterial hypertension.
    Johnson JA; Hemnes AR; Perrien DS; Schuster M; Robinson LJ; Gladson S; Loibner H; Bai S; Blackwell TR; Tada Y; Harral JW; Talati M; Lane KB; Fagan KA; West J
    Am J Physiol Lung Cell Mol Physiol; 2012 Mar; 302(5):L474-84. PubMed ID: 22180660
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mice expressing BMPR2R899X transgene in smooth muscle develop pulmonary vascular lesions.
    West J; Harral J; Lane K; Deng Y; Ickes B; Crona D; Albu S; Stewart D; Fagan K
    Am J Physiol Lung Cell Mol Physiol; 2008 Nov; 295(5):L744-55. PubMed ID: 18723761
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dysregulated Smooth Muscle Cell BMPR2-ARRB2 Axis Causes Pulmonary Hypertension.
    Wang L; Moonen JR; Cao A; Isobe S; Li CG; Tojais NF; Taylor S; Marciano DP; Chen PI; Gu M; Li D; Harper RL; El-Bizri N; Kim YM; Stankunas K; Rabinovitch M
    Circ Res; 2023 Mar; 132(5):545-564. PubMed ID: 36744494
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BMPR2 gene delivery reduces mutation-related PAH and counteracts TGF-β-mediated pulmonary cell signalling.
    Feng F; Harper RL; Reynolds PN
    Respirology; 2016 Apr; 21(3):526-32. PubMed ID: 26689975
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inflammation, endothelial injury, and persistent pulmonary hypertension in heterozygous BMPR2-mutant mice.
    Song Y; Coleman L; Shi J; Beppu H; Sato K; Walsh K; Loscalzo J; Zhang YY
    Am J Physiol Heart Circ Physiol; 2008 Aug; 295(2):H677-90. PubMed ID: 18552156
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Raf/ERK drives the proliferative and invasive phenotype of BMPR2-silenced pulmonary artery endothelial cells.
    Awad KS; Elinoff JM; Wang S; Gairhe S; Ferreyra GA; Cai R; Sun J; Solomon MA; Danner RL
    Am J Physiol Lung Cell Mol Physiol; 2016 Jan; 310(2):L187-201. PubMed ID: 26589479
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hyperoxia synergizes with mutant bone morphogenic protein receptor 2 to cause metabolic stress, oxidant injury, and pulmonary hypertension.
    Fessel JP; Flynn CR; Robinson LJ; Penner NL; Gladson S; Kang CJ; Wasserman DH; Hemnes AR; West JD
    Am J Respir Cell Mol Biol; 2013 Nov; 49(5):778-87. PubMed ID: 23742019
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endothelin-Bone morphogenetic protein type 2 receptor interaction induces pulmonary artery smooth muscle cell hyperplasia in pulmonary arterial hypertension.
    Maruyama H; Dewachter C; Belhaj A; Rondelet B; Sakai S; Remmelink M; Vachiery JL; Naeije R; Dewachter L
    J Heart Lung Transplant; 2015 Mar; 34(3):468-78. PubMed ID: 25447587
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Codependence of Bone Morphogenetic Protein Receptor 2 and Transforming Growth Factor-β in Elastic Fiber Assembly and Its Perturbation in Pulmonary Arterial Hypertension.
    Tojais NF; Cao A; Lai YJ; Wang L; Chen PI; Alcazar MAA; de Jesus Perez VA; Hopper RK; Rhodes CJ; Bill MA; Sakai LY; Rabinovitch M
    Arterioscler Thromb Vasc Biol; 2017 Aug; 37(8):1559-1569. PubMed ID: 28619995
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phenotypically Silent Bone Morphogenetic Protein Receptor 2 Mutations Predispose Rats to Inflammation-Induced Pulmonary Arterial Hypertension by Enhancing the Risk for Neointimal Transformation.
    Tian W; Jiang X; Sung YK; Shuffle E; Wu TH; Kao PN; Tu AB; Dorfmüller P; Cao A; Wang L; Peng G; Kim Y; Zhang P; Chappell J; Pasupneti S; Dahms P; Maguire P; Chaib H; Zamanian R; Peters-Golden M; Snyder MP; Voelkel NF; Humbert M; Rabinovitch M; Nicolls MR
    Circulation; 2019 Oct; 140(17):1409-1425. PubMed ID: 31462075
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bmpr2 Mutant Rats Develop Pulmonary and Cardiac Characteristics of Pulmonary Arterial Hypertension.
    Hautefort A; Mendes-Ferreira P; Sabourin J; Manaud G; Bertero T; Rucker-Martin C; Riou M; Adão R; Manoury B; Lambert M; Boet A; Lecerf F; Domergue V; Brás-Silva C; Gomez AM; Montani D; Girerd B; Humbert M; Antigny F; Perros F
    Circulation; 2019 Feb; 139(7):932-948. PubMed ID: 30586714
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serotonin 2B Receptor Antagonism Prevents Heritable Pulmonary Arterial Hypertension.
    West JD; Carrier EJ; Bloodworth NC; Schroer AK; Chen P; Ryzhova LM; Gladson S; Shay S; Hutcheson JD; Merryman WD
    PLoS One; 2016; 11(2):e0148657. PubMed ID: 26863209
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modulation of Endothelial Bone Morphogenetic Protein Receptor Type 2 Activity by Vascular Endothelial Growth Factor Receptor 3 in Pulmonary Arterial Hypertension.
    Hwangbo C; Lee HW; Kang H; Ju H; Wiley DS; Papangeli I; Han J; Kim JD; Dunworth WP; Hu X; Lee S; El-Hely O; Sofer A; Pak B; Peterson L; Comhair S; Hwang EM; Park JY; Thomas JL; Bautch VL; Erzurum SC; Chun HJ; Jin SW
    Circulation; 2017 Jun; 135(23):2288-2298. PubMed ID: 28356442
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NF-κB mediated miR-130a modulation in lung microvascular cell remodeling: Implication in pulmonary hypertension.
    Li L; Kim IK; Chiasson V; Chatterjee P; Gupta S
    Exp Cell Res; 2017 Oct; 359(1):235-242. PubMed ID: 28755990
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Let-7a-transfected mesenchymal stem cells ameliorate monocrotaline-induced pulmonary hypertension by suppressing pulmonary artery smooth muscle cell growth through STAT3-BMPR2 signaling.
    Cheng G; Wang X; Li Y; He L
    Stem Cell Res Ther; 2017 Feb; 8(1):34. PubMed ID: 28187784
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BMPRII influences the response of pulmonary microvascular endothelial cells to inflammatory mediators.
    Vengethasamy L; Hautefort A; Tielemans B; Belge C; Perros F; Verleden S; Fadel E; Van Raemdonck D; Delcroix M; Quarck R
    Pflugers Arch; 2016 Nov; 468(11-12):1969-1983. PubMed ID: 27816994
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dysregulated zinc and sphingosine-1-phosphate signaling in pulmonary hypertension: Potential effects by targeting of bone morphogenetic protein receptor type 2 in pulmonary microvessels.
    Tran HB; Maiolo S; Harper R; Zalewski PD; Reynolds PN; Hodge S
    Cell Biol Int; 2021 Nov; 45(11):2368-2379. PubMed ID: 34347342
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CCL5 deficiency rescues pulmonary vascular dysfunction, and reverses pulmonary hypertension via caveolin-1-dependent BMPR2 activation.
    Nie X; Tan J; Dai Y; Liu Y; Zou J; Sun J; Ye S; Shen C; Fan L; Chen J; Bian JS
    J Mol Cell Cardiol; 2018 Mar; 116():41-56. PubMed ID: 29374556
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.